Figure 6.

Monalizumab Enhances Human NK Cell-Mediated ADCC and Anti-tumor Activity of Monalizumab and Cetuximab

(A) Left panel: NK cells from healthy donors were co-cultured with the CAL-27 SCCHN cell line in the presence or absence of monalizumab (Mona) or cetuximab (Ctx). The data shown are the frequencies of CD137-expressing NKG2A⁺ NK cells after 24 hr. N = 13. Student t test comparing the Mona + Cetux combination with Ctx as single agent ^∗∗∗∗p < 0.0001. Right panel: NK cells from healthy donors were co-cultured with 721.221 cells expressing HLA-Cw3 and HLA-Cw4 in the presence or absence of monalizumab (Mona) or obinutuzumab (Obz). The data shown are the frequencies of CD137-expressing NKG2A⁺ NK cells after 24 hr. N = 12. Student’s t test comparing the Mona + Obz combination with Obz as a single agent. ^∗∗∗∗p < 0.0001.

(B) Waterfall plot of the largest change in target lesion relative to the baseline.

(C) Spider plot of the largest change in target lesion relative to the baseline.

The patient who died early, due to disease progression, before the first assessment is not represented in these graphs. In accordance with RECIST 1.1, a confirmation of response was required.

(D) Example of a partial response after treatment with the Mona + Cetux combination in a patient with recurrent oral cavity cancer (left masticator space) previously treated by surgery, chemotherapy (cisplatin), and radiation therapy.

See also Table 1.